相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1968
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Mindfulness-Oriented Recovery Enhancement (MORE) generates a 12-to-1 benefit-to-cost ratio, yielding lifetime savings of $324,489 per patient. - MORE reduced opioid misuse by 45% in the underlying randomized clinical trial of 250 adults with chronic pain misusing prescribed opioids. - The cost-effectiveness of MORE is two to six times greater than residential or intensive outpatient addiction treatment approaches. - Researchers call for wider integration of MORE into health systems, including primary care, to intervene before misuse progresses to severe addiction.
- Researchers at UC San Diego discovered a previously unknown biological pathway involving the Ral protein and cathepsin A (CTSA) that drives LDL receptor depletion in response to high dietary cholesterol. - Blocking CTSA with a small molecule inhibitor stabilized LDL receptors and dramatically lowered circulating LDL cholesterol in mice, according to findings published in Nature. - The CTSA inhibitor has already completed a Phase 1 clinical trial for heart failure and was proven safe in humans, potentially accelerating its path to a Phase 2 trial for high cholesterol. - The newly identified pathway is completely separate from those targeted by existing cholesterol-lowering drugs such as statins and PCSK9 inhibitors, offering a novel therapeutic option for patients who cannot reach safe cholesterol levels.
- A study of over 17,000 adults found that several modifiable dementia risk factors have a disproportionately larger impact on cognitive decline in women compared to men. - Cardiovascular and metabolic conditions, including hypertension and higher BMI, showed stronger negative associations with cognitive function in women, despite some being more prevalent in men. - Women were nearly twice as likely to report depression (17% vs. 9%) and had higher rates of physical inactivity and sleep problems, while men had higher rates of hearing loss and diabetes. - Researchers advocate for sex-specific prevention strategies, emphasizing that tailoring interventions to how strongly risk factors affect each sex could reduce dementia burden, especially for women.
- UC San Diego researchers led the world's first clinical trial proving cancer treatments can be safely personalized using individual tumor DNA profiles, with results published in Journal of Clinical Oncology. - The I-PREDICT trial treated 210 advanced cancer patients with 157 different treatment regimens, including 103 novel drug combinations, with nearly 95% of patients having unique tumor DNA profiles. - Patients whose therapies were most closely matched to their tumor mutations experienced improved treatment response and survival rates without increased side effects. - The study establishes a foundation for precision oncology moving from "one-size-fits-all" to "one-size-fits-one" cancer treatment approaches.
• Ruxolitinib cream demonstrates positive long-term safety profile in atopic dermatitis patients, with lower rates of cutaneous infections compared to untreated populations according to extended clinical trial data. • The JAK inhibitor topical treatment outperforms mid-potency corticosteroids while being suitable for delicate skin areas including the face and body folds, potentially preventing progression to systemic therapy. • Experts emphasize shared decision-making as crucial in atopic dermatitis management, with treatment plans tailored to patient history, disease severity, and consideration of the skin microbiome's role in disease pathogenesis.
- A clinical trial revealed that cetuximab is more effective than durvalumab in treating head and neck cancers for patients who cannot tolerate cisplatin. - The study found a significantly higher probability of being alive and disease-free at two years with cetuximab compared to durvalumab (64% vs. 51%). - The trial was halted early to allow all participants to switch to cetuximab due to its clear benefits, reinforcing its role as a strong alternative to cisplatin. - Cetuximab's effectiveness was consistent regardless of HPV infection status, suggesting broad applicability in this patient population.
